AbbVie (ABBV) Goodwill & Intangibles (2012 - 2026)
AbbVie (ABBV) posted quarterly Goodwill & Intangibles of $86.4 billion for Q1 2026, down 7.82% year-over-year from $93.8 billion in Q1 2025, and down 2.08% quarter-over-quarter from $88.3 billion in Q4 2025.
AbbVie (ABBV) Goodwill & Intangibles (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Goodwill & Intangibles for 15 consecutive years, with $86.4 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill & Intangibles fell 7.82% year-over-year to $86.4 billion; the TTM figure through Mar 2026 stood at $86.4 billion (down 7.82% YoY), while the FY2025 annual figure was $88.3 billion, down 7.1% from the prior year.
- Goodwill & Intangibles eased to $86.4 billion in Q1 2026 per ABBV's latest filing, from $88.3 billion in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $106.3 billion in Q1 2022 and bottomed at $36.3 billion in Q3 2025.
- Historically, Goodwill & Intangibles has averaged $92.0 billion across 5 years, with a median of $95.0 billion in 2024.
- Annual changes were most pronounced in 2024 — Goodwill & Intangibles grew 12.4% — and 2025, when it slumped 64.35%.
- AbbVie's Goodwill & Intangibles stood at $99.6 billion in 2022, then dropped by 11.74% to $87.9 billion in 2023, then gained by 8.1% to $95.0 billion in 2024, then dropped by 7.1% to $88.3 billion in 2025, then fell by 2.08% to $86.4 billion in 2026.
- Business Quant data shows ABBV's Goodwill & Intangibles at $86.4 billion in Q1 2026, $88.3 billion in Q4 2025, and $36.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84.66 Bn |
| Mar 31, 2026 | 86.44 Bn |
| Dec 31, 2025 | 88.28 Bn |
| Sep 30, 2025 | 36.34 Bn |
| Jun 30, 2025 | 92.67 Bn |
| Mar 31, 2025 | 93.77 Bn |
| Dec 31, 2024 | 95.02 Bn |
| Sep 30, 2024 | 101.94 Bn |
| Jun 30, 2024 | 93.63 Bn |
| Mar 31, 2024 | 95.65 Bn |
| Dec 31, 2023 | 87.90 Bn |
| Sep 30, 2023 | 90.69 Bn |
| Jun 30, 2023 | 95.09 Bn |
| Mar 31, 2023 | 97.07 Bn |
| Dec 31, 2022 | 99.60 Bn |
| Sep 30, 2022 | 100.45 Bn |
| Jun 30, 2022 | 103.85 Bn |
| Mar 31, 2022 | 106.28 Bn |
| Dec 31, 2021 | 108.33 Bn |
| Sep 30, 2021 | 109.75 Bn |